Thyroid nodules, prevalent in up to 65% of the population, pose a significant diagnostic challenge due to the risk of malignancy. The intricacies of their evaluation necessitate a comprehensive understanding for effective patient management.
Most thyroid nodules are asymptomatic and discovered incidentally. However, symptoms such as dysphagia, dyspnea, or rapid growth may suggest malignancy. A meticulous physical examination can reveal a firm, fixed, or irregular nodule, indicative of a higher cancer risk.
High-resolution neck ultrasonography is the imaging modality of choice for initial evaluation. It provides information about the size, number, echogenicity, and calcification of nodules, which are crucial for risk stratification.
Thyroid-stimulating hormone (TSH) level assessment is recommended for all nodules. A suppressed TSH level warrants a radionuclide thyroid scan to evaluate for hyperfunctioning nodules, which are usually benign.
FNAC remains the most reliable method for differentiating benign from malignant nodules. The decision to perform FNAC is based on the nodule's size, ultrasonographic features, and patient's risk factors.
For nodules with indeterminate FNAC results, molecular testing can be useful. It identifies specific gene mutations or gene expression patterns, aiding in the prediction of malignancy.
Management depends on the nodule's cytological diagnosis, size, and associated symptoms. Options range from surveillance to thyroidectomy, with the choice of treatment tailored to individual patient circumstances.
Thyroid nodule evaluation is a complex process requiring a multifaceted approach. An understanding of this process aids in accurate diagnosis, appropriate risk stratification, and effective management, ultimately improving patient outcomes.
1.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
2.
In patients with prostate cancer, second-generation antiandrogens may worsen fatigue, falls, and cognitive decline.
3.
Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes
4.
Booze and Pancreatic Cancer Risk; From 'Hospice' to 'Hope'; Gen Z-ers Skip Screening
5.
Cancer screening rates down among American adults
1.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
2.
The Pros and Cons of Using Cyclophosphamide in Cancer Treatment
3.
A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies
4.
The Truth About Marijuana and Its Effect on Mental Health
5.
Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
2.
From Guidelines to Practice: Hematology
3.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation